Real-world treatment for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: information from a Japanese hospital claims database
Modern Rheumatology · 2025
DOI: 10.1093/mr/roaf082 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, 2025. Verfasst von Takashi Funatogawa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Clinical Development Department, Chugai Pharmaceutical Co., Ltd, 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo 103-8324, Japan. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Scleroderma, Systemic, Biological Products, Immunosuppressive Agents. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
The 2023 EULAR guidelines for systemic sclerosis (SSc) recommend biologics (rituximab, tocilizumab), mycophenolate mofetil (MMF), and nintedanib in addition to cyclophosphamide for interstitial lung disease (ILD). This study investigated recent actual use of these drugs in Japan.
Methods
We analysed data from a Japanese hospital claims database (2020–3), identifying patients with SSc disease codes (ICD-10 M34.x) and/or ILD codes. Patients with coexisting autoimmune disease codes were also included.
Results
Of 14,522 SSc patients, 2080 (14.3%) received small-molecule drugs and 618 (4.3%) received biologics. For SSc, common first small-molecule drugs were methotrexate (24.2%), nintedanib (19.5%), tacrolimus (17.9%), and MMF (16.8%); common first biologics were rituximab (44.2%) and tocilizumab (29.1%). Of 4890 SSc-ILD patients, 1081 (22.1%) received small-molecule drugs and 282 (5.8%) received biologics. For SSc-ILD, common first small-molecule drugs were nintedanib (30.8%), tacrolimus (20.9%), and MMF (18.3%); common first biologics were rituximab (51.8%) and tocilizumab (25.2%). Rituximab showed the greatest increase in use for both SSc and SSc-ILD between 2020 and 2023. Common subsequent treatments following rituximab or intravenous cyclophosphamide (which are typically administered for a limited duration) were nintedanib, MMF, and rituximab.
Conclusions
Recent actual drug use in Japan has been aligning increasingly closely with the EULAR recommendations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Clinical Development Department, Chugai Pharmaceutical Co., Ltd, 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo 103-8324, Japan.
Zitieren
APA
Funatogawa, T., Mii, K., Kojima, K., Aoki, Y., Matsubara, Y., & Hoshiba, M. (2025). Real-world treatment for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: information from a Japanese hospital claims database. Modern Rheumatology. https://doi.org/10.1093/mr/roaf082
Vancouver
Funatogawa T, Mii K, Kojima K, Aoki Y, Matsubara Y, Hoshiba M. Real-world treatment for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: information from a Japanese hospital claims database. Modern Rheumatology. 2025. doi:10.1093/mr/roaf082
BibTeX
@article{Funatogawa2025,
author = {Funatogawa, Takashi and Mii, Kazuma and Kojima, Kazuki and Aoki, Yuka and Matsubara, Yasuaki and Hoshiba, Mariko},
title = {Real-world treatment for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: information from a Japanese hospital claims database},
journal = {Modern Rheumatology},
year = {2025},
doi = {10.1093/mr/roaf082}
}
EUVIMED